Dogs suffering from muloskeletal diseases and injuries, such as osteoarthritis and injured tendons and ligaments, can soon benefit from a new treatment reviewed by the U.S. Food and Drug Administration (FDA).
PrecisePRP Canine, a leucoreduced, allogeneic, pooled, freeze-dried platelet-rich plasma (PRP) developed by VetStem, Inc., has received the FDA review clearance. According to the agency’s announcement, this product is “the first animal cell, tissue, and cell- and tissue-based product (ACTP) intended for intra-articular use to undergo FDA review and receive this determination.” Each vial of the injectable contains a consistent dose of four billion platelets at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1,500 white blood cells per microliter.
There is great interest in platelet-rich plasma in both human and veterinary medicine, according to the FDA. Some of its applications include cases in dermatology, ophthalmology, and musculoskeletal diseases.
“We are proud to have collaborated with the FDA under this new review program and applaud their requirements for the review process,” says Bob Harman, DVM, found and CEO of VetStem, Inc.
PrecisePRP Canine is an off-the-shelf product and does not require a blood draw or centrifugation, nor refrigeration. The product is slated to launch in the U.S. in May.
For more information, visit the FDA website.
